This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .
Are Needle-Free Injections a Useful Alternative for Growth Hormone Therapy in Children? Safety and Pharmacokinetics of Growth Hormone Delivered by a New Needle-Free Injection Device Compared to a Fine Gauge Needle
The clinical safety , use and pharmacokinetics of a new needle-free device for delivery of growth hormone ( GH ) were compared with those of conventional needle injection devices . In an open-label , r and omized , 4-period crossover study , 18 healthy adults received single subcutaneous injections of  Genotropin administered by the Genotropin ZipTip needle-free device and by conventional injection . Bioequivalence was established between the devices . In a separate open-label , r and omized , multicenter , 2-period crossover study , pediatric patients underwent 2-weeks Genotropin treatment administered by the Genotropin ZipTip and by a fine-gauge needle device ( > 95 % used the Genotropin Pen ) . In total , 128/133 patients who were treated completed the study .  Genotropin ZipTip was well tolerated and > 50 % of patients found no difference between the devices for all parameters assessed . After study completion , > 20 % patients preferred to continue using Genotropin ZipTip . Although statistical analyses demonstrated superiority of the Genotropin Pen versus Genotropin ZipTip for bleeding , pain , soreness , and bruising , Genotropin ZipTip was considered to provide a safe and bioequivalent alternative to needle injection
This SR highlights the lack of long-term RCTs reporting final height data and other important qualitative outcomes , such as quality of life .
ABSTRACT Genotropin ( somatropin ) is licensed for the treatment of children with growth hormone deficiency , Prader-Willi syndrome , Turner syndrome , chronic renal insufficiency and in children born small for gestational age .
This systematic review ( SR ) evaluated the clinical efficacy and effectiveness of Genotropin in these conditions to inform a NICE Technology Appraisal of growth hormone for the treatment of growth failure in children .